Bleeding in Patients with Atrial Fibrillation Plus Coronary Artery Disease under Triple anti-Coagulant Therapy
Men's Health Journal,
Vol. 5 No. 1 (2021),
6 Dey 2021
,
Page e3
https://doi.org/10.22037/mhj.v5i1.33712
Abstract
Introduction: Regarding scarce knowledge about bleeding in non-valvular atrial fibrillation (AF) patients with simultaneous coronary artery disease (CAD) under triple anti-coagulant therapy, this study was carried out to recognize the risk of hemorrhage and preventive programming.
Materials and Methods: In this performed prospective, 150 consecutive patients with non-valvular atrial fibrillation and concurrent coronary disease, candidate for triple therapy with Asprin 80 mg, Clopidogrel 75 mg and Rivaroxaban 15 mg (in Shohada, Loghman, Modarres, and Labafinezhad centers, in Tehran, Iran during Jan 2019 to Jan 2020 were enrolled and the incidence rate of bleeding and compliance were evaluated for one month.
Results: The results in this study demonstrated that 87.3% had compliance and completely use three drugs. Bleeding occurred in 0.6 % (4 patients), no major bleeding , only one minor bleeding as GIB, three minimal cases (totally 4 bleeding cases), 3 cases with epistaxis, 7 patients with ecchymosis, 6 subjects with hematuria, no one required discontinuation of drug. Diabetes mellitus, hypertension, female sex, older age, higher HASBLED Score, and higher CHADS-VASC Score were related to lack of compliance (P < 0.05).
Conclusion: Incidence rate of bleeding in atrial fibrillation plus coronary concurrent patients, candidate for triple therapy with ASA, Clopidogrel and Rivaroxaban is low. Also the bleeding is minor and the compliance is high showing that majority of cases use routinely these triple therapy regimen.
- Atrial fibrillation
- Bleeding
- CAD
- Compliance
- Rivaroxaban
How to Cite
References
Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115-9.
Savelieva I, Bajpai A, John Camm A. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Annals of medicine. 2007;39(5):371-91.
Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension. 2000;35(4):858-63.
Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nature Reviews Cardiology. 2014;11(11):639.
Lip GY, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, et al. Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States. International journal of clinical practice. 2016;70(9):752-63.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Thromb Haemost. 2013;110(6):1087-107.
Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Journal of thrombosis and thrombolysis. 2017;43(3):365-79.
Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. The American journal of medicine. 2010;123(7):638-45. e4.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383(9921):955-62.
Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thrombosis and haemostasis. 2014;112(05):783-8.
Cheung K-S, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World journal of gastroenterology. 2017;23(11):1954.
Alirhayim Z. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation: author reply. The American Journal of Cardiology. 2014;114(2):327.
Qureshi W, Mittal C, Patsias I, Garikapati K, Kuchipudi A, Cheema G, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. The American Journal of Cardiology. 2014;113(4):662-8.
Wu H, Jing Q, Wang J, Guo X. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. Journal of critical care. 2011;26(4):434. e1-. e6.
Bikedli B, Sharif-Kashani B. Venous thromboembolism: a Persian Perspective to Prevention, Diagnosis, and Treatment. North American Thrombosis Forum 2010. 2012.
Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. The American journal of medicine. 2007;120(8):700-5.
Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European heart journal. 2011;32(19):2387-94.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883-91.
Habert JS. Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. International journal of general medicine. 2016;9:337.
Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. Journal of the American Heart Association. 2016;5(6):e003725.
Vimalesvaran K, Dockrill SJ, Gorog DA. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. Vascular Health and Risk Management. 2018;14:13.
Mendoza-Sanchez J, Silva F, Rangel L, Jaramillo L, Mendoza L, Garzon J, et al. Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis. PlOS One. 2018;13(5):e0196361.
Coleman C, Bunz T, Eriksson D, Meinecke AK, Sood N. Effectiveness and safety of rivaroxaban vs warfarin in people with non‐valvular atrial fibrillation and diabetes: an administrative claims database analysis. Diabetic Medicine. 2018;35(8):1105-10.
Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. Journal of the American Heart Association. 2018;7(8):e008643.
- Abstract Viewed: 136 times
- pdf Downloaded: 155 times